Protocol Ledger

NCT05856526 · Phase II/III · TERMINATED

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Interventional Phase II/III clinical trial protocol NCT05856526 sponsored by Boehringer Ingelheim in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-12 Enrollment: 43 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05856526
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)43 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05856526
Protocol FieldVerified Registry Value
NCT IdentifierNCT05856526
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment43 participants (ACTUAL)
Registered Start Date2023-06-12
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI